首页> Biochemical Pharmacology> Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity

Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity

导出原文传递

翻译打印收藏纠错

第一作者： Steri,R.

作者： Steri,R. ^[1] ; Achenbach,J. ; Steinhilber,D. ; Schubert-Zsilavecz,M. ; Proschak,E.

作者单位： Institute of Pharmaceutical Chemistry, ZAFES/LiFF/Goethe-University Frankfurt, Max-von-Laue-Str. 9 ^[1]

关键词 Antidiabetic compounds Drug repurposing Farnesoid X receptor Imatinib Self-organizing maps Virtual screening

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Biochemical Pharmacology

2012年83卷12期

1674-1681页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Biochemical Pharmacology

2012年83卷12期

1674-1681页

检索历史清除

Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity

Biochemical Pharmacology

相似文献

同项目论文

Biochemical Pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity

Biochemical Pharmacology

相似文献

同项目论文

Biochemical Pharmacology

相关期刊

检索历史清除